Syndax Pharmaceuticals (SNDX)

Executive Summary

Syndax Pharmaceuticals (NASDAQ: SNDX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for difficult-to-treat cancers. Its pipeline of 37 candidates is built around two core platforms: menin inhibitors and BET inhibitors, targeting hematologic malignancies and solid tumors with high unmet need. The lead asset, revumenib (a menin inhibitor), has shown promise in NPM1-mutant acute myeloid leukemia (AML) and received Breakthrough Therapy designation from the FDA. Additionally, axatilimab (a CSF-1R antibody) is being evaluated in idiopathic pulmonary fibrosis (IPF), representing a potential expansion beyond oncology. The company also has one commercial product, generating early revenue, though the pipeline remains the primary value driver.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for axatilimab in idiopathic pulmonary fibrosis (IPF)40% success
• 2026Update on revumenib combination trials in acute myeloid leukemia (AML)60% success
• H1 2027Potential regulatory submission for revumenib in NPM1-mutant AML50% success